{"log_id": 1023645510215355401, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0.013788, "average": 0.914834, "min": 0.512422}, "location": {"width": 936, "top": 399, "height": 29, "left": 335}, "words": "2C9,2C19、2D6或3A4,它也不会诱导 CYPIA2、2B6、2C9、2C19或3A4因此,本品"}, {"probability": {"variance": 0.016025, "average": 0.939994, "min": 0.560724}, "location": {"width": 680, "top": 436, "height": 34, "left": 331}, "words": "与通过这cYP代谢的药物之间不可能有药代动力学相互作用"}, {"probability": {"variance": 0.03302, "average": 0.882111, "min": 0.392627}, "location": {"width": 294, "top": 477, "height": 29, "left": 376}, "words": "其它药物对布他的影响"}, {"probability": {"variance": 0.015564, "average": 0.936691, "min": 0.528997}, "location": {"width": 893, "top": 518, "height": 31, "left": 379}, "words": "非布司他通过多种代谢酶以结合和氧化两种方式代谢,每个酶亚型的相关作用还不消"}, {"probability": {"variance": 0.015397, "average": 0.93692, "min": 0.470493}, "location": {"width": 742, "top": 557, "height": 31, "left": 331}, "words": "楚。本昌和制或诱导某一特定酶业型的药物之间一般不会有相互作用"}, {"probability": {"variance": 0.001065, "average": 0.970608, "min": 0.908046}, "location": {"width": 239, "top": 598, "height": 29, "left": 379}, "words": "体内药物相互作用研究"}, {"probability": {"variance": 0.019259, "average": 0.918062, "min": 0.507706}, "location": {"width": 895, "top": 639, "height": 34, "left": 379}, "words": "茶碱:本品与茶碱同时服泪时无需调整给药剂量,本品(80mg每B一次)与茶载同服将"}, {"probability": {"variance": 0.03172, "average": 0.901263, "min": 0.379234}, "location": {"width": 943, "top": 678, "height": 34, "left": 331}, "words": "导致茶碱的Cnx和AUC分别增大6%和65%。础的这两个参数变化认为是无统计学"}, {"probability": {"variance": 0.013632, "average": 0.934997, "min": 0.493983}, "location": {"width": 943, "top": 717, "height": 38, "left": 328}, "words": "义或不显著。但是,试验表明,本显对嘌呤氧化酶的抑制作用导致经尿排泄的1甲基黄"}, {"probability": {"variance": 0.020098, "average": 0.904662, "min": 0.527468}, "location": {"width": 943, "top": 758, "height": 34, "left": 328}, "words": "呤(茶碱的一种主要代谢含量增大约400倍。关于人体长期暴露于1-甲基黄嘌呤的安全"}, {"probability": {"variance": 0.023163, "average": 0.895626, "min": 0.427145}, "location": {"width": 945, "top": 799, "height": 34, "left": 326}, "words": "性,目前未开展相关试酸研究。在同服本品与茶碱时,应考虑到1-甲黄嘌呤的体内"}, {"probability": {"variance": 0.000214, "average": 0.984827, "min": 0.970206}, "location": {"width": 50, "top": 842, "height": 27, "left": 331}, "words": "蓄积"}, {"probability": {"variance": 0.042084, "average": 0.843663, "min": 0.364964}, "location": {"width": 900, "top": 881, "height": 38, "left": 374}, "words": "秋水仙:本品和状水仙索联合药时,二者都无进行量调整本品(40ng,每"}, {"probability": {"variance": 0.031219, "average": 0.846757, "min": 0.427587}, "location": {"width": 936, "top": 922, "height": 36, "left": 331}, "words": "日一次)与秋水仙素(0.6mng,每日两次合给到,导致布司他C1m和AUC分别增加12%"}, {"probability": {"variance": 0.010279, "average": 0.94618, "min": 0.482678}, "location": {"width": 941, "top": 961, "height": 36, "left": 331}, "words": "和7%,此外,秋水仙(0.6rg,每日两次)与本品(每日120mg)联合给药,导致上午和下午"}, {"probability": {"variance": 0.029343, "average": 0.927555, "min": 0.3197}, "location": {"width": 694, "top": 1005, "height": 34, "left": 328}, "words": "给药后 Cu, AUC出现小于11%的变化。这些变化不具临床意义"}, {"probability": {"variance": 0.024947, "average": 0.906936, "min": 0.359393}, "location": {"width": 888, "top": 1046, "height": 34, "left": 376}, "words": "萘生:本品和普生联给,一者都无需进行剂址调推本品(80mg.每日一次"}, {"probability": {"variance": 0.019806, "average": 0.90001, "min": 0.413156}, "location": {"width": 909, "top": 1085, "height": 36, "left": 331}, "words": "与普生(5C0ng,每日两次)联合给药,导致非布司他Cm和AUd别增加28%和405"}, {"probability": {"variance": 0.024439, "average": 0.914193, "min": 0.416159}, "location": {"width": 813, "top": 1126, "height": 34, "left": 331}, "words": "该增加无临风意义,而且,普生的Cn或AUC均无显著变化(<2"}, {"probability": {"variance": 0.036264, "average": 0.876284, "min": 0.360794}, "location": {"width": 660, "top": 1169, "height": 36, "left": 376}, "words": "吲哚美辛:本品平哚美辛联合给药时,二者都无需进行量"}, {"probability": {"variance": 0.040648, "average": 0.791809, "min": 0.512986}, "location": {"width": 159, "top": 1171, "height": 34, "left": 1112}, "words": "本点(B0mg,每"}, {"probability": {"variance": 0.031773, "average": 0.84539, "min": 0.416704}, "location": {"width": 737, "top": 1203, "height": 47, "left": 331}, "words": "日一次吗哚美辛50mg,每日两)联合给药非布司他或学"}, {"probability": {"variance": 0.047193, "average": 0.702294, "min": 0.478432}, "location": {"width": 89, "top": 1215, "height": 27, "left": 1176}, "words": "uC产"}, {"probability": {"variance": 0.010771, "average": 0.934967, "min": 0.697437}, "location": {"width": 233, "top": 1251, "height": 31, "left": 333}, "words": "生任何显著变化(<7%)"}, {"probability": {"variance": 0.040515, "average": 0.828759, "min": 0.364392}, "location": {"width": 895, "top": 1293, "height": 38, "left": 379}, "words": "氢氯嗪:本品与氢喇联合给药付,无需进行铜,品(0m与刚嗪"}, {"probability": {"variance": 0.027635, "average": 0.901267, "min": 0.377902}, "location": {"width": 751, "top": 1336, "height": 34, "left": 342}, "words": "5ng)联合给药,布他的Cm或AUC未产生任何临床意义的变化"}, {"probability": {"variance": 0.090855, "average": 0.698258, "min": 0.396836}, "location": {"width": 68, "top": 1341, "height": 27, "left": 1203}, "words": "且"}, {"probability": {"variance": 0.005239, "average": 0.951226, "min": 0.772744}, "location": {"width": 242, "top": 1375, "height": 31, "left": 331}, "words": "尿酸浓度未受显著影响"}, {"probability": {"variance": 0.033719, "average": 0.893598, "min": 0.395673}, "location": {"width": 902, "top": 1416, "height": 43, "left": 376}, "words": "华法林:华法林与本品合给药无进行剂量调整木品(80mg,每日一次)与华法林"}, {"probability": {"variance": 0.021252, "average": 0.936737, "min": 0.399735}, "location": {"width": 941, "top": 1459, "height": 36, "left": 331}, "words": "合给药,对健康受试者华法林药代动力学无影响,本品给药也未对际标准化比值"}, {"probability": {"variance": 0.04122, "average": 0.863072, "min": 0.383066}, "location": {"width": 388, "top": 1503, "height": 27, "left": 347}, "words": "(NR〕和血子Ⅶ话性产生彩响"}, {"probability": {"variance": 0.007291, "average": 0.944721, "min": 0.658525}, "location": {"width": 895, "top": 1544, "height": 34, "left": 376}, "words": "地帕明:CYP2D6底物如地背帕明)与本品联合给药,无需进行剂量调整。体外和体"}, {"probability": {"variance": 0.033306, "average": 0.889256, "min": 0.353268}, "location": {"width": 941, "top": 1583, "height": 34, "left": 333}, "words": "内试表明非布他是CYP2D6的弱制剂。非布司他(120mg,每日一次与池帕明"}, {"probability": {"variance": 0.017737, "average": 0.90594, "min": 0.552438}, "location": {"width": 929, "top": 1626, "height": 31, "left": 342}, "words": "5mg合给药导致地背拍明的Cm(16%)和AUC2%)增加,这与2羟基地铂明与地"}, {"probability": {"variance": 0.020228, "average": 0.942548, "min": 0.362258}, "location": {"width": 422, "top": 1667, "height": 31, "left": 331}, "words": "帕明的代谢比率下降17%有关根据AC"}, {"probability": {"variance": 0.001544, "average": 0.972375, "min": 0.904583}, "location": {"width": 84, "top": 1708, "height": 29, "left": 326}, "words": "【贮藏】"}, {"probability": {"variance": 0.026686, "average": 0.931791, "min": 0.390724}, "location": {"width": 322, "top": 1749, "height": 29, "left": 376}, "words": "光,密封,不超过25℃保存"}, {"probability": {"variance": 0.000165, "average": 0.989621, "min": 0.968457}, "location": {"width": 82, "top": 1791, "height": 27, "left": 328}, "words": "【包装】"}, {"probability": {"variance": 0.037692, "average": 0.840017, "min": 0.449332}, "location": {"width": 303, "top": 1829, "height": 36, "left": 379}, "words": "铝型包装,10片/,1板/盒"}, {"probability": {"variance": 0.00251, "average": 0.961839, "min": 0.876166}, "location": {"width": 105, "top": 1873, "height": 31, "left": 328}, "words": "【有效期"}, {"probability": {"variance": 1.8e-05, "average": 0.996599, "min": 0.989428}, "location": {"width": 77, "top": 1916, "height": 27, "left": 381}, "words": "24个月"}, {"probability": {"variance": 0.000203, "average": 0.990306, "min": 0.962138}, "location": {"width": 130, "top": 1957, "height": 31, "left": 326}, "words": "【执行标准"}], "language": 3}